| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OMCL | Common Stock | Award | $0 | +9.52K | +36.29% | $0.00 | 35.8K | Mar 14, 2022 | Direct | F1 |
| transaction | OMCL | Common Stock | Tax liability | -$113K | -863 | -2.41% | $131.21 | 34.9K | Mar 14, 2022 | Direct | F2 |
| holding | OMCL | Common Stock | 31K | Mar 14, 2022 | Direct |
| Id | Content |
|---|---|
| F1 | Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 4,760 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 9,520 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022. |
| F2 | Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units. |